Reversible posterior leukoencephalopathy syndrome in cancer

  title={Reversible posterior leukoencephalopathy syndrome in cancer},
  author={Christopher J. Vaughn and Louann Zhang and David Schiff},
  journal={Current Oncology Reports},
Reversible posterior leukoencephalopathy syndrome (RPLS) is a subacute neurological syndrome typically manifesting with headache, cortical blindness, and seizures. The syndrome is associated with risk factors such as malignant hypertension, eclampsia, and renal failure. Numerous case reports depict its occurrence in cancer patients. The direct causal relationship for the mechanism of RPLS in cancer patients has not yet been defined. Cytotoxic chemotherapy may cause direct endothelium damage… 

Reversible posterior leukoencephalopathy syndrome after carboplatin and paclitaxel regimen for lung cancer.

The case of a 62-year-old man who was diagnosed with RPLS after receiving carboplatin and paclitaxel chemotherapy for lung cancer appears to be the first recognized association of RPLs with this regimen.

Fatal posterior revesible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature

A case of fatal PRES-associated coma induced by bevacizumab in metastatic colorectal cancer is presented and a literature review was conducted by utilizing PubMed Database.

Reversible Posterior Leukoencephalopathy Syndrome Induced by Pazopanib

The case of a 40 years old female patient with heavily pre-treated metastatic renal cell carcinoma who received pazopanib as salvage treatment is presented, which is the first case of pazobanib induced reversible posterior leukoencephalopathy syndrome.

Reversible posterior leukoencephalopathy induced by carboplatin and etoposide

The case of a 69-year-old lady who collapsed with seizure activity after receiving carboplatin and etoposide chemotherapy for small cell lung cancer is described.

Reversible Posterior Leukoencephalopathy Syndrome Associated with Concurrent Bevacizumab, Gemcitabine, and Oxaliplatin for Cholangiocarcinoma

The first reported case of RPLS associated with bevacizumab, gemcitabine, and oxaliplatin combination chemotherapy is presented and suggests that gradual progression of hypertension and proteinuria may be early warning signs before the onset of R PLS that should alarm clinicians.

Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer

RPLS is a rare, but serious, clinicoradiologic syndrome which has been described as an adverse effect of many anti-angiogenic agents and should also be considered in patients on cediranib who present with neurologic symptoms along with vasogenic edema seen on MRI.

Reversible Posterior Leukoencephalopathy Syndrome after Eribulin Mesylate Chemotherapy for Breast Cancer

A case of rare adverse events in a breast cancer patient who was undergoing eribulin chemotherapy who had generalized tonic-clonic seizure with eyeball deviation to right and loss of consciousness is reported.

Reversible Posterior Leukoencephalopathy Syndrome in Patients Undergoing Chemotherapy for Solid Tumors. A Case Report and Review of the Literature

Clinicians need to have a high index of suspicion and the combination of the clinical picture with the characteristic neuroimaging findings can help in the prompt diagnosis of Reversible posterior leukoencephalopathy syndrome.



Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies

Two cases of adults undergoing treatment for hematological malignancies who developed RPLS are reported, and the importance of early recognition and institution of appropriate management in reducing the risk of development of permanent neurological disability is emphasized.

Chemotherapy induced reversible posterior leukoencephalopathy syndrome.

Hodgkin's disease-related central nervous system angiopathy presenting as reversible posterior leukoencephalopathy.

A case of Hodgkin's disease (HD)-related central nervous system (CNS) angiitis with neuroimaging finding suggestive of reversible posterior leukoencephalopathy syndrome is described and the pathophysiology of RPLS in cases with CNSAngiitis is discussed.

Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.

Clinical and radiographic evidence consistent with reversible posterior leukoencephalopathy syndrome was found following the administration of irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) regimen chemotherapy and bevacizumab.

A reversible posterior leukoencephalopathy syndrome.

Reversible, predominantly posterior leukoencephalopathy may develop in patients who have renal insufficiency or hypertension or who are immunosuppressed and the findings on neuroimaging are characteristic of subcortical edema without infarction.

Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome.

Clinical and neuroradiologic features corresponded to reversible posterior leukoencephalopathy syndrome (RPLS), which some immunosuppressive and chemotherapeutic drugs have been reported to trigger.

Reversible posterior leukoencephalopathy in patients with systemic lupus erythematosus.

Posterior leukoencephalopathy syndrome

  • R. Garg
  • Medicine, Psychology
    Postgraduate medical journal
  • 2001
Posterior leukoencephalopathy syndrome is a newly recognised brain disorder that predominantly affects the cerebral white matter that is clinically characterised by headache, nausea and vomiting, seizures, visual disturbances, altered sensorium, and occasionally focal neurological deficit.


This work presents a case of sirolimus-induced posterior reversible encephalopathy syndrome (PRES) with a lobar intracranial hemorrhage in a 51-year-old woman recipient of a single lung transplant 2 years prior to presentation.

Reversible Posterior Leukoencephalopathy Syndrome after Treatment of Diffuse Large B-Cell Lymphoma

The reversible posterior leukoencephalopathy syndrome is believed to be the result of altered cerebral autoregulation with impaired blood flow control and resultant endothelial damage caused by different situations and agents.